Shares of Edgewise Therapeutics, Inc. (EWTX) surged 5.33% in the pre-market session on Friday, as analysts expressed optimism about the healthcare company's prospects.
Scotiabank initiated coverage on EWTX with an Outperform rating and a $50 price target, citing expectations of positive momentum for the company. The firm believes that Edgewise Therapeutics' pipeline and potential in the healthcare sector could drive significant growth in the future.
The positive analyst sentiment has boosted investor confidence in EWTX, leading to the stock's pre-market rally. As more analysts weigh in on the company, the market's outlook on Edgewise Therapeutics may continue to improve, potentially supporting further upward movement in the stock price.